PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis




CME logo 2017The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cardiovascular Research Foundation designates this activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Documentation of awarded credit is provided for participants in exchange for completed activity evaluations.



As transcatheter aortic valve replacement (TAVR) continues to show great promise in long-term patient outcomes, growing evidence supports the use of TAVR across a broader risk spectrum. The recent PARTNER 3 trial examined the potential for expanding TAVR to patients with low surgical risk. This enduring activity will discuss emerging clinical science pertaining to TAVR use in low-risk patient populations, considerations for integrating new TAVR knowledge into practice, and the shifting roles of transcatheter (TAVR) and surgical replacement (SAVR) as new clinical knowledge in these areas continues to emerge.


By the end of this activity, participants should be able to:

1) Describe study design of the PARTNER 3 trial (patient selection & recruitment, key metrics, primary clinical endpoints) and resultant implications for significance of results.

2) Define principal clinical findings relevant to the landscape of TAVR indications and TAVR in low-risk patient populations.

3) Identify key treatment considerations for optimal selection and management of low-risk TAVR patients.


This activity is designed for interventional cardiologists, cardiac surgeons, clinical cardiologists, vascular medicine specialists, and other healthcare professionals.


Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs.


It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity.

Discussion of off-label product usage and/or off-label product use is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the conference directors of this activity.

Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Faculty not complying with this policy are not permitted to participate in this activity.


KEY: (G/R) Grant Support/Research Contract (C/H/S) Consultant Fee/Honoraria/Speaker’s Bureau (E) Equity (R/I) Royalty/Intellectual Property Rights (S) Salary/Salary Support (O) Other Financial Benefit

Michael J. Mack: (G/R) Abbott Vascular, Medtronic, Edwards Lifesciences

Martin B. Leon: (G/R) Abbott Vascular, Medtronic, Edwards Lifesciences, Boston Scientific, (C/H/S) Boston Scientific, W.L. Gore & Associates, (E) Mitralign, Medinol, Cathworks, Elixir, GDS, Valve Medical

Susheel K. Kodali: (C/H/S) Claret Medical, Meril Lifesciences, Abbott Vascular

Vinod H. Thourani: (G/R) (C/H/S) Abbott Vascular, Boston Scientific, Edwards Lifesciences, (C/H/S) W.L. Gore & Associates

Planning Committee

Robert Blanco (Planner)
(S) Cardiovascular Research Foundation


This program is sponsored by the Cardiovascular Research Foundation. It is supported through an educational grant from Edwards Lifesciences and was developed without influence from commercial supporters. 


To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Robert Blanco at rblanco@crf.org .

We Recommend